Chronische inflammatorische demyelinisierende Polyneuropathie

M. Balke; G. Wunderlich; A. Brunn; G. R. Fink; H. C. Lehmann

doi:10.1055/s-0042-120226

Fortschritte der Neurologie · Psychiatrie, Inhaltsverzeichnis

Fortschr Neurol Psychiatr 2016; 84(12): 756-769
DOI: 10.1055/s-0042-120226

Fort- und Weiterbildung

Chronische inflammatorische demyelinisierende Polyneuropathie

Chronic Inflammatory Demyelinating Polyneuropathy

Autor*innen

M. Balke

¹Klinik und Poliklinik für Neurologie, Universitätsklinikum Köln
G. Wunderlich

¹Klinik und Poliklinik für Neurologie, Universitätsklinikum Köln
A. Brunn

²Institut für Neuropathologie, Universitätsklinikum Köln
G. R. Fink

¹Klinik und Poliklinik für Neurologie, Universitätsklinikum Köln

³Institut für Neurowissenschaften und Medizin (INM-3), Forschungszentrum Jülich
H. C. Lehmann

¹Klinik und Poliklinik für Neurologie, Universitätsklinikum Köln

Abstract

Zusammenfassung

Die chronische inflammatorische demyelinisierende Polyneuropathie (CIDP) ist eine entzündliche, progredient oder schubförmig verlaufende Erkrankung des peripheren Nervensystems mit individuell unterschiedlich verteiltem, typischerweise symmetrischem Muster distaler und proximaler Paresen und fakultativ sensiblen Defiziten. Daneben gibt es atypische Varianten, die mit raschem Beginn, ausschließlich sensiblen Defiziten, fokalem oder sehr asymmetrischem Ausfallmuster einhergehen können. Die Neuropathie ist autoimmun vermittelt, an der Pathogenese sind Autoantikörper, Makrophagen, B- und T-Zellen beteiligt. Die Diagnose wird anhand klinischer Symptome, charakteristischer Veränderungen in der Elektrophysiologie und anhand des Liquorbefundes gestellt. In Zweifelsfällen kann der Nachweis entzündlicher Infiltrate in einer Biopsie des N. suralis die Diagnose stützen. Zukünftig wird vermutlich auch der MRT und der Nervensonografie Bedeutung bei der Diagnosestellung zukommen. Therapeutisch sind Steroide, Immunglobuline und Plasmapherese gleichermaßen wirksam. Darüber hinaus werden Immunsuppressiva und zunehmend auch monoklonale Antikörper eingesetzt.

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic progressive or relapsing autoimmune neuropathy with heterogeneous clinical presentation. Symptoms typically include symmetrical, proximal and/or distal paresis and sensory loss. Atypical CIDP variants are increasingly recognized, including subtypes with rapid onset as well as variants with pure sensory, focal or marked asymmetrical deficits. Diagnosis is established by compatible symptoms, characteristic electrophysiological features and cerebrospinal fluid analysis. In unequivocal cases, inflammatory infiltrates in sural nerve biopsy support the diagnosis. Recent studies suggest that diagnostic imaging techniques such as MRI and nerve ultrasound may become useful tools for establishing the diagnosis. First-line therapies include immunoglobulines, steroids, and plasmapheresis. Immunosuppressant agents and monoclonal antibodies are used in therapy-refractory cases or as cortison-saving agents.

Volltext

Referenzen

Literatur
1 Mathey EK, Park SB, Hughes RA et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 2015; 86: 973-985
2 Lehmann HC. Chronisch inflammatorische demyelinisierende Polyneuropathie. Aktuelle Entwicklungen bei Diagnose und Therapie. Nervenheilkunde 2014; 33: 535-539
3 Mahdi-Rogers M, Hughes RA. Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol 2014; 21: 28-33
4 Merkies IS, Kieseier BC. Fatigue, Pain, Anxiety and Depression in Guillain-Barre Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Eur Neurol 2016; 75: 199-206
5 Kleyman I, Brannagan 3rd TH. Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Neurol Neurosci Rep 2015; 15: 47
6 Busby M, Donaghy M. Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients. J Neurol 2003; 250: 714-724
7 Rotta FT et al. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000; 173: 129-139
8 Viala K, Maisonobe T, Stojkovic T et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2010; 15: 50-56
9 Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010; 9: 402-412
10 Katz JS et al. Distal acquired demyelinating symmetric neuropathy. Neurology 2000; 54: 615-620
11 Viala K, Renie L, Maisonobe T et al. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 2004; 127 (09) 2010-2017
12 Ruts L, Drenthen J, Jacobs BC et al. Distinguishing „acute-onset“ CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010; 74: 1680-1686
13 Illes Z, Kondo T, Newcombe J et al. Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000; 164: 4375-4381
14 Schmidt B, Toyka KV, Kiefer R et al. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996; 19: 474-487
15 Winer J, Hughes S, Cooper J et al. gamma delta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy. J Neurol 2002; 249: 616-621
16 Yang M, Peyret C, Shi XQ et al. Evidence from Human and Animal Studies: Pathological Roles of CD8(+) T Cells in Autoimmune Peripheral Neuropathies. Front Immunol 2015; 6: 532
17 Schneider-Hohendorf T, Schwab N, Uceyler N et al. CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012; 78: 402-408
18 Ritter C, Förster D, Albrecht P et al. IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). J Neuroimmunol 2014; 274: 225-229
19 Hartung HP, Reiners K, Schmidt B et al. Serum interleukin-2 concentrations in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991; 30: 48-53
20 Maimone D, Annunziata P, Simone IL et al. Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 1993; 47: 55-61
21 Sainaghi PP, Collimedaglia L, Alciato F et al. The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barre syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine 2010; 51: 138-143
22 Lehmann HC, Hughes RA, Kieseier BC et al. Recent developments and future directions in Guillain-Barre syndrome. J Peripher Nerv Syst 2012; 17 (Suppl. 03) 57-70
23 Meyer zu Hörste G, Hartung HP, Kieseier BC. From bench to bedside – experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 2007; 3: 198-211
24 Salomon B, Rhee L, Bour-Jordan H et al. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med 2001; 194: 677-684
25 Oh SJ, Claussen GC, Odabasi Z et al. Multifocal demyelinating motor neuropathy: pathologic evidence of 'inflammatory demyelinating polyradiculoneuropathy'. Neurology 1995; 10: 1828-1832
26 Yan WX, Taylor J, Andrias-Kauba S et al. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 2000; 47: 765-775
27 Lehmann HC, Meyer zu Hörste G, Kieseier BC et al. Pathogenesis and treatment of immune-mediated neuropathies. Ther Adv Neurol Disord 2009; 2: 261-281
28 Querol L, Nogales-Gadea G, Rojas-Garcia R et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2013; 73: 370-380
29 Querol L, Nogales-Gadea G, Rojas-Garcia R et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 2014; 82: 879-886
30 Miura Y, Devaux JJ, Fukami Y et al. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 2015; 138 (06) 1484-1491
31 Doppler K, Appeltshauser L, Kramer HH et al. Contactin-1 and Neurofascin-155/-186 Are Not Targets of Auto-Antibodies in Multifocal Motor Neuropathy. PLoS One 2015; 10: e0134274
32 Doppler K, Werner C, Sommer C. Disruption of nodal architecture in skin biopsies of patients with demyelinating neuropathies. J Peripher Nerv Syst 2013; 18: 168-176
33 Devaux JJ, Miura Y, Fukami Y et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 2016; 86: 800-807
34 Breiner A, Brannagan 3rd TH. Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2014; 50: 40-46
35 Van den Bergh PY, Hadden RD, Bouche PY et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. Eur J Neurol 2010; 17: 356-363
36 Bril V, Banach M, Dalakas MC et al. Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve 2010; 42: 492-497
37 Hughes RA, Donofrio P, Bril V et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7: 136-144
38 Vital A, Lagueny A, Julien J et al. Chronic inflammatory demyelinating polyneuropathy associated with dysglobulinemia: a peripheral nerve biopsy study in 18 cases. Acta Neuropathol 2000; 100: 63-68
39 Webster HD, Schröder JM, Asbury AK et al. The role of Schwann cells in the formation of „onion bulbs“ found in chronic neuropathies. J Neuropathol Exp Neurol 1967; 26: 276-299
40 Shibuya K, Sugiyama A, Ito S et al. Reconstruction magnetic resonance neurography in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2015; 77: 333-337
41 Mathys C, Aissa J, Meyer Zu Horste G et al. Peripheral neuropathy: assessment of proximal nerve integrity by diffusion tensor imaging. Muscle Nerve 2013; 48: 889-896
42 Kakuda T, Fukuda H, Tanitame K et al. Diffusion tensor imaging of peripheral nerve in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a feasibility study. Neuroradiology 2011; 53: 955-960
43 Kerasnoudis A, Pitarokoili K, Behrendt V et al. Bochum ultrasound score versus clinical and electrophysiological parameters in distinguishing „acute-onset“ chronic from acute inflammatory demyelinating polyneuropathy. Muscle Nerve 2015; 51: 846-852
44 Kerasnoudis A, Pitarokoili K, Gold R et al. Bochum ultrasound score allows distinction of chronic inflammatory from multifocal acquired demyelinating polyneuropathies. J Neurol Sci 2015; 348: 211-215
45 Kerasnoudis A, Pitarokoili K, Behrendt V et al. Nerve ultrasound score in distinguishing chronic from acute inflammatory demyelinating polyneuropathy. Clin Neurophysiol 2014; 125: 635-641
46 Kerasnoudis A, Pitarokoili K, Gold R et al. Nerve Ultrasound and Electrophysiology for Therapy Monitoring in Chronic Inflammatory Demyelinating Polyneuropathy. J Neuroimaging 2015; 25: 931-939
47 Bucher F, Schneider C, Blau T et al. Small-Fiber Neuropathy Is Associated With Corneal Nerve and Dendritic Cell Alterations: An In Vivo Confocal Microscopy Study. Cornea 2015; 34: 1114-1119
48 Tavakoli M, Quattrini C, Abbott C et al. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care 2010; 33: 1792-1797
49 Stettner M, Hinrichs L, Guthoff R et al. Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy. Ann Clin Transl Neurol 2016; 3: 88-100
50 Schneider C, Bucher F, Cursiefen C et al. Corneal confocal microscopy detects small fiber damage in chronic inflammatory demyelinating polyneuropathy (CIDP). J Peripher Nerv Syst 2014; 19: 322-327
51 Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology 2015; 85: 498-504
52 Farhad K, Traub R, Ruzhansky KM et al. Causes of neuropathy in patients referred as "idiopathic neuropathy". Muscle Nerve 2016; 53: 856-861
53 Cocito D, Paolasso I, Antonini G et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2010; 17: 289-294
54 Nobile-Orazio E, Cocito D, Jann S et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 2012; 11: 493-502
55 Dyck PJ et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50: 621-637
56 Dyck PJ, O'Brien PC, Oviatt KF et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11: 136-141
57 van Schaik IN, Eftimov F, van Doorn PA et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9: 245-253
58 Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 2005; 62: 249-254
59 Ritter C, Bobylev I, Lehmann HC. Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins. J Neuroinflammation 2015; 12: 148
60 Quast I, Cueni F, Nimmerjahn F et al. Deregulated Fcgamma receptor expression in patients with CIDP. Neurol Neuroimmunol Neuroinflamm 2015; 2: e148
61 Tackenberg B, Jelcic I, Baerenwaldt A et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A 2009; 106: 4788-4792
62 Hahn AF, Bolton CF, Zochodne D et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996; 119 (04) 1067-1077
63 Vermeulen M, van Doorn PA, Brand A et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993; 56: 36-39
64 Thompson N, Choudhary P, Hughes RA et al. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996; 243: 280-285
65 Eftimov F, Winer JB, Vermeulen M et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2013;
66 Dyck PJ, Litchy WJ, Kratz KM et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36: 838-845
67 Hadden RD, Marreno F. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction. Ther Adv Neurol Disord 2015; 8: 14-19
68 Markvardsen LH, Debost JC, Harbo T et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2013; 20: 836-842
69 Leussink VI, Hartung HP, Kieseier BC et al. Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies. Ther Adv Neurol Disord 2016; 9: 336-343
70 Yoon MS, Gold R, Kerasnoudis A. Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders. Ther Adv Neurol Disord 2015; 8: 153-159
71 Cocito D, Merola A, Peci E et al. Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. J Neurol 2014; 261: 2159-2164
72 Markvardsen LH, Harbo T, Sindrup SH et al. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol 2014; 21: 1465-1470
73 Markvardsen LH, Christiansen I, Andersen H et al. Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin. Basic Clin Pharmacol Toxicol 2015; 117: 409-412
74 Rajabally YA, Kearney DA. Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study. J Neurol Sci 2011; 308: 124-127
75 Gallia F, Balducci C, Nobile-Orazio E. Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune mediated neuropathies. J Peripher Nerv Syst 2016; 21: 82-84
76 Kuitwaard K, van den Berg LH, Vermeulen M et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2010; 81: 1374-1379
77 Lunn MP, Ellis L, Hadden RD et al. A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst 2016; 21: 33-37
78 Berger M. Adverse effects of IgG therapy. J Allergy Clin Immunol Pract 2013; 1: 558-566
79 Chan YC, Allen DC, Fialho D et al. Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2006; 77: 114-116
80 Koller H, Kieseier BC, Jander S et al. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005; 352: 1343-1356
81 Tackenberg B, Lunemann JD, Steinbrecher A et al. Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology 2007; 68: 1622-1629
82 Hahn AF, Bolton CF, Pillay N et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996; 119 (04) 1055-1066
83 Lehmann HC, Hartung HP, Hetzel GR et al. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol 2006; 63: 1066-1071
84 Lehmann HC, Hartung HP, Hetzel GR et al. Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 2006; 63: 930-935
85 Yoon MS, Chan A, Gold R. Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Ther Adv Neurol Disord 2011; 4: 193-200
86 Inoue A, Oguchi K, Iwahashi T et al. Prominent effect of immunoadsorption plasmapheresis therapy in a patient with chronic inflammatory demyelinating polyneuropathy associated with hepatitis B infection. Ther Apher 1998; 2: 305-307
87 Ullrich H, Mansouri-Taleghani B, Lackner KJ et al. Chronic inflammatory demyelinating polyradiculoneuropathy: superiority of protein A immunoadsorption over plasma exchange treatment. Transfus Sci 1998; 19: 33-38
88 Zinman LH, Sutton D, Ng E et al. A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. Transfus Apher Sci 2005; 33: 317-324
89 Dyck PJ, O’Brien P, Swanson C et al. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985; 35: 1173-1176
90 Hadden RD, Sharrack B, Bensa S et al. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999; 53: 57-61
91 Hughes RA, Gorson KC, Cros D et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010; 74: 651-657
92 RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009; 8: 158-164
93 Good JL, Chehrenama M, Mayer RF et al. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998; 51: 1735-1738
94 Barnett MH, Pollard JD, Davies L et al. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998; 21: 454-460
95 Matsuda M, Hoshi K, Gono T et al. Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2004; 224: 29-35
96 Odaka M, Tatsumoto M, Susuki K et al. Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. J Neurol Neurosurg Psychiatry 2005; 76: 1115-1120
97 Cocito D, Grimaldi S, Paolasso I et al. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol 2011; 18: 1417-1421
98 Bedi G, Brown A, Tong T et al. Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry 2010; 81: 634-636
99 Radziwill AJ, Schweikert K, Kuntzer T et al. Mycophenolate mofetil for chronic inflammatory demyelinating polyradiculoneuropathy: An open-label study. Eur Neurol 2006; 56: 37-38
100 Benedetti L, Grandis M, Nobbio L et al. Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve 2004; 29: 748-749
101 Benedetti L, Briani C, Franciotta D et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82: 306-308
102 Benedetti L, Franciotta D, Beronio A et al. Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura. Muscle Nerve 2008; 38: 1076-1077
103 Briani C, Zara G, Zambello R et al. Rituximab-responsive CIDP. Eur J Neurol 2004; 11: 788
104 Munch C, Anagnostou P, Meyer R et al. Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurol Sci 2007; 256: 100-102
105 Gorson KC, Natarajan N, Ropper AH et al. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007; 35: 66-69
106 Querol L, Rojas-Garcia R, Diaz-Manera J et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2015; 2: e149
107 Marsh EA, Hirst CL, Llewelyn JG et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol 2010; 257: 913-919
108 Vallat JM, Mathis S, Ghorab K et al. Natalizumab as a Disease-Modifying Therapy in Chronic Inflammatory Demyelinating Polyneuropathy – A Report of Three Cases. Eur Neurol 2015; 73: 294-302
109 Wolf C, Menge T, Stenner MP et al. Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2010; 67: 881-883
110 Merkies IS, Schmitz PI. Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients’ own clinical judgement in immune-mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2006; 77: 970-972
111 van Nes SI, Vanhoutte EK, van Doorn PA et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 2011; 76: 337-345
112 Mendell JR, Barohn RJ, Freimer ML et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56: 445-449
113 Panaite PA, Renaud S, Kraftsik R et al. Impairment and disability in 20 CIDP patients according to disease activity status. J Peripher Nerv Syst 2013; 18: 241-246
114 Eftimov F, Vermeulen M, van Doorn PA et al. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 2012; 78: 1079-1084
115 Gorson KC, van Schaik IN, Merkies IS et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010; 15: 326-333